1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > RegeneRx Biopharmaceuticals, Inc. - Product Pipeline Review - 2014

RegeneRx Biopharmaceuticals, Inc. - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 28 pages

RegeneRx Biopharmaceuticals, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘RegeneRx Biopharmaceuticals, Inc. - Product Pipeline Review - 2014’, provides an overview of the RegeneRx Biopharmaceuticals, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of RegeneRx Biopharmaceuticals, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of RegeneRx Biopharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of RegeneRx Biopharmaceuticals, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the RegeneRx Biopharmaceuticals, Inc.’s pipeline products

Reasons to buy

- Evaluate RegeneRx Biopharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of RegeneRx Biopharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the RegeneRx Biopharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of RegeneRx Biopharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of RegeneRx Biopharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of RegeneRx Biopharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

RegeneRx Biopharmaceuticals, Inc. - Product Pipeline Review - 2014
Table of Contents
RegeneRx Biopharmaceuticals, Inc. Snapshot 4
RegeneRx Biopharmaceuticals, Inc. Overview 4
Key Information 4
Key Facts 4
RegeneRx Biopharmaceuticals, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
RegeneRx Biopharmaceuticals, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
RegeneRx Biopharmaceuticals, Inc. - Pipeline Products Glance 9
RegeneRx Biopharmaceuticals, Inc. - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
RegeneRx Biopharmaceuticals, Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
RegeneRx Biopharmaceuticals, Inc. - Drug Profiles 12
RGN-137 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
RGN-259 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
RGN-352 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
RegeneRx Biopharmaceuticals, Inc. - Pipeline Analysis 17
RegeneRx Biopharmaceuticals, Inc. - Pipeline Products by Route of Administration 17
RegeneRx Biopharmaceuticals, Inc. - Pipeline Products by Molecule Type 18
RegeneRx Biopharmaceuticals, Inc. - Recent Pipeline Updates 19
RegeneRx Biopharmaceuticals, Inc. - Dormant Projects 24
RegeneRx Biopharmaceuticals, Inc. - Discontinued Pipeline Products 25
Discontinued Pipeline Product Profiles 25
RGN-259 25
RGN-457 25
RegeneRx Biopharmaceuticals, Inc. - Locations And Subsidiaries 26
Head Office 26
Appendix 27
Methodology 27
Coverage 27
Secondary Research 27
Primary Research 27
Expert Panel Validation 27
Contact Us 28
Disclaimer 28

List of Tables

RegeneRx Biopharmaceuticals, Inc., Key Information 4
RegeneRx Biopharmaceuticals, Inc., Key Facts 4
RegeneRx Biopharmaceuticals, Inc. - Pipeline by Indication, 2014 6
RegeneRx Biopharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 7
RegeneRx Biopharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 8
RegeneRx Biopharmaceuticals, Inc. - Phase II, 2014 9
RegeneRx Biopharmaceuticals, Inc. - Phase I, 2014 10
RegeneRx Biopharmaceuticals, Inc. - Preclinical, 2014 11
RegeneRx Biopharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 17
RegeneRx Biopharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 18
RegeneRx Biopharmaceuticals, Inc. - Recent Pipeline Updates, 2014 19
RegeneRx Biopharmaceuticals, Inc. - Dormant Developmental Projects,2014 24
RegeneRx Biopharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 25

List of Figures

RegeneRx Biopharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2014 6
RegeneRx Biopharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 7
RegeneRx Biopharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 8
RegeneRx Biopharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2014 17
RegeneRx Biopharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2014 18

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Galena Biopharma, Inc. (GALE) - Financial and Strategic SWOT Analysis Review

Galena Biopharma, Inc. (GALE) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2016
  • by Global Data

Summary Galena Biopharma, Inc. (Galena) is a biotechnology company that discovers, develops and commercializes therapies for the treatment of unmet medical needs, and advance care. Its pipeline products ...

ARCA biopharma, Inc. (ABIO) - Financial and Strategic SWOT Analysis Review

ARCA biopharma, Inc. (ABIO) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2016
  • by Global Data

Summary ARCA biopharma, Inc. (ARCA), formerly Nuvelo, Inc., is a biopharmaceutical company. The company focuses on the development of genetically targeted therapies for cardiovascular diseases. Its product ...

Can-Fite BioPharma Ltd. (CFBI) - Financial and Strategic SWOT Analysis Review

Can-Fite BioPharma Ltd. (CFBI) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2016
  • by Global Data

Summary Can-Fite BioPharma Ltd. (Can-Fite) is a biopharmaceutical company that concentrates on the discovery and clinical development of drugs. The company's pipeline product portfolio comprise CF101, ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.